Rosa has confirmed kidney disease, type two diabetes, and an A one C already at her individualized goal. That glucose result does not settle the question of kidney and cardiovascular protection. Compare therapies using the actual population and clinical outcome studied. Consider an appropriate S G L T two inhibitor, review blood pressure treatment, and assess whether additional evidence-based therapy fits her kidney function, potassium, other conditions, and preferences. A reduction in urine albumin is useful information, but it is not the same endpoint as fewer kidney failures or cardiovascular events. Discuss benefits, adverse effects, affordability, and monitoring together. The takeaway: treat the person's organ risk, not only the glucose number.